Friday, 23 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial

January 6, 2025
China's State Council Aims to Enhance Drug and Medical Device Regulation by 2027
Policy / Regulatory

China’s State Council Aims to Enhance Drug and Medical Device Regulation by 2027

January 6, 2025
Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding
Company

Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding

January 5, 2025
AstraZeneca's Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment
CompanyDrug

AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment

January 3, 2025
NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients
CompanyDrug

NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients

January 3, 2025
Gilead Sciences' Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
CompanyDrug

Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection

January 3, 2025
WinHealth Pharma's Difelikefalin Receives NMPA Review for Market Approval
CompanyDrug

WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval

January 3, 2025
Shanghai Enacts New Regulations for Drug and Medical Device Administration
Policy / Regulatory

Shanghai Enacts New Regulations for Drug and Medical Device Administration

January 3, 2025
Thederma's TAN-118 Receives Tacit Clinical Approval from China's CDE for Global Trials
CompanyDrug

Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials

January 3, 2025
Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement
CompanyDeals

Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement

January 3, 2025
Innovent Biologics' Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC
CompanyDrug

Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC

January 3, 2025
MabPharm's CMAB807 Biosimilar Infliximab Approved in Pakistan
CompanyDrug

MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan

February 12, 2025
1 2 … 285 286 287 288 289 290
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up